Supplier
Gabecare Directrx INC
Gabecare Directrx INC was paid $2.27M by Medicaid between Jan 2018 and Dec 2024, across 14 billing codes. Its largest line is J7677, Revefenacin inhalation solution, fda-approved final product, non-compounded, administered through dme, 1 microgram — 55% of everything it billed.
33Billing provider infoGABECARE DIRECTRX INC
TROY, MI 48084
TROY, MI 48084
33aNPI1194725705assigned 07/26/2005
33bProvider typeDurable Medical Equipment & Medical Supplies
28Total paid$2.27M
24GClaims65,546
24DCodes billed14
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Durable Medical Equipment & Medical Supplies providers in Michigan
Rank by total paid#36 of 290
Median peer was paid$97K
This provider vs. median23×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 775 | $8K | |
| 2019 | 3,564 | $102K | |
| 2020 | 7,454 | $309K | |
| 2021 | 7,748 | $386K | |
| 2022 | 10,224 | $344K | |
| 2023 | 14,730 | $527K | |
| 2024incomplete | 21,051 | $593K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J7677 | Revefenacin inhalation solution, fda-approved final product, non-compounded, administered through dme, 1 microgram | 55% | 12,436 | 7,678 | $1.26M |
| J7606 | Formoterol fumarate, inhalation solution, fda approved final product, non-compounded, administered through dme, unit dose form, 20 micrograms | 20% | 6,259 | 5,320 | $462K |
| J7605 | Arformoterol, inhalation solution, fda approved final product, non-compounded, administered through dme, unit dose form, 15 micrograms | 10% | 4,050 | 3,434 | $228K |
| J7626 | Budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 0.5 mg | 6.4% | 9,743 | 8,209 | $145K |
| Q0513 | Pharmacy dispensing fee for inhalation drug(s); per 30 days | 4.6% | 14,636 | 12,171 | $105K |
| J7699 | Noc drugs, inhalation solution administered through dme | 1.6% | 388 | 329 | $37K |
| G0333 | Pharmacy dispensing fee for inhalation drug(s); initial 30-day supply as a beneficiary | <1% | 991 | 812 | $11K |
| E0570 | Nebulizer, with compressor | <1% | 3,971 | 3,893 | $9K |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 2,545 | 2,140 | $6K |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 3,544 | 3,075 | $5K |
| A7003 | Administration set, with small volume nonfiltered pneumatic nebulizer, disposable | <1% | 4,426 | 3,873 | $2K |
| A7005 | Administration set, with small volume nonfiltered pneumatic nebulizer, non-disposable | <1% | 299 | 259 | $686.20 |
2 more codes
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBERISHAJ, AMANDA (VICE PRESIDENT)